International Union of Basic and Clinical Pharmacology. CXXII. Applying an objective evaluation to the status of class A orphan G protein-coupled receptors Authors: Stephen P.H. Alexander, Kirstie A. Bennett, Andrew J. Brown, Michelle Glass, David E. Gloriam, Julien Hanson, Paul A. Insel, Eamonn Kelly, Christopher J. Langmead, Kirill A. Martemyanov, Rick R. Neubig, Stefan Offermanns, Mette M. Rosenkilde, Gunnar Schulte, Nicola J. Smith, Huixian Wu, Elena Faccenda, Simon D. Harding, Anthony P. Davenport Published: 2026 ABSTRACT In this review, we, on behalf of the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology, describe criteria for assessing the evidence for pairing receptors with endogenous/physiological ligands for formal receptor deorphanization. This process is illustrated through consideration of the class A G protein-coupled receptors (GPCRs) not yet formally paired with an endogenous/physiological ligand by the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology. Of the 67 orphan class A GPCRs considered, 25 class A GPCRs have no identified endogenous agonists, although 5 (GPR21, GPR27, GPR52, GPR85, and GPR88) have synthetic ligands that have the potential to be used as tools for uncovering physiological roles and further pharmacological properties of these receptors. Surprisingly, 6 orphan GPCRs (GPR135, GPR152, GPR153, MRGPRF, MRGPRG, and MRGPRX3) have no clear pharmacology or phenotype reported following genetic disruption. Thirty-two orphan GPCRs have been paired with at least 1 endogenous agonist (mainly lipids and their derivatives, peptides, and other metabolites), but further characterization is required from the scientific community to validate these results. We identify 10 orphan class A GPCRs for which there are plausible grounds for considering deorphanization: GPR4 (protons), GPR15 (GPR15L), GPR31 (12S-hydroxyeicosatetraenoic acid), GPR39 (zinc divalent ions, Zn2+), GPR65 (protons), GPR68 (protons), GPR132 (9-hydroxyoctadecadienoic acid), GPR183 (7α,25-dihydroxycholesterol), MRGPRD (β-alanine), and MRGPRX1 (bovine adrenal medulla peptide 8-22). The issue of nomenclature for these 10 GPCRs will be considered by further subcommittees of the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology. We hope this review will prompt further investigations into these members of the currently most widely clinically exploited protein superfamily.Significance StatementThe use of systematic, rational nomenclature for drug targets provides a framework to ensure consistent identification and rapid recognition. Given that G protein-coupled receptors have fundamental physiological roles and are widespread targets of drugs in current clinical use, we hope the target summary and deorphanization criteria provided here will prompt renewed efforts to investigate these orphan receptors as regulators of physiology and as opportunities for future therapeutic exploitation. Introduction and scope NC-IUPHAR is the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (https://www.guidetopharmacology.org/nciuphar.jsp). One of the central objectives of NC-IUPHAR is to provide guidelines for the nomenclature and classification of biological targets of drugs, which we present through an online, freely accessible data base at www.guidetopharmacology.org. The intention of the NC-IUPHAR-recommended nomenclature is to provide guidance on the naming of drug targets that is clear, logical, and consistent so that the broader scientific community avoids confusion and saves time and energy. NC-IUPHAR has previously published a G protein-coupled receptor (GPCR) list,1 which was updated to reflect preliminary pairings between orphan GPCRs and endogenous ligands, providing initial criteria for deorphanization.2 In this reflection on the current state of this field of research, we update the criteria that NC-IUPHAR applies to progress the formal deorphanization of a receptor and use the class A GPCRs to illustrate the process. Over the last 30 years, many publications from NC-IUPHAR have appeared in Pharmacological Reviews and have identified the preferred nomenclature for a number of families of class A GPCRs (Table 1). In the absence of a formal publication, NC-IUPHAR has established a nomenclature for several families communicated via the website www.guidetopharmacology.org. These include the bile acid receptor, dopamine receptors, galanin receptors, glycoprotein hormone receptors, gonadotropin-releasing hormone receptors, melanin-concentrating hormone receptors, melanocortin receptors, motilin receptor, neuromedin U receptors, neuropeptide FF/neuropeptide AF receptors, neuropeptide S receptor, neuropeptide W/neuropeptide B receptors, neurotensin receptors, opioid receptors, platelet-activating factor receptor, prokineticin receptors, prolactin-releasing peptide receptor, QRFP receptor, tachykinin receptors, thyrotropin-releasing hormone receptors, and vasopressin and oxytocin receptors (Table 1).Table 1Human class A G protein-coupled receptor families, which the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology considers have an established endogenous/physiological ligandFamilyFamily5-Hydroxytryptamine receptors88,89Melanin-concentrating hormone receptorsAcetylcholine receptors (muscarinic)90Melanocortin receptorsAdenosine receptors91,92Melatonin receptors93Adrenoceptors94,95Motilin receptorAngiotensin receptors96,97Neuromedin U receptorsApelin receptor98,99Neuropeptide FF/neuropeptide AF receptorsBile acid receptorNeuropeptide S receptorBombesin receptors100Neuropeptide W/neuropeptide B receptorsBradykinin receptors101Neuropeptide Y receptors102Cannabinoid receptors83,103Neurotensin receptorsChemerin receptors104Opioid receptorsChemokine receptors3,105, 106, 107Orexin receptors108,109Cholecystokinin receptors110Oxoglutarate receptor2Complement peptide receptors111P2Y receptors112Dopamine receptorsPlatelet-activating factor receptorEndothelin receptors113,114Prokineticin receptorsFormylpeptide receptors85Prolactin-releasing peptide receptorFree fatty acid receptors115Prostanoid receptors116, 117, 118G protein-coupled estrogen receptor119Proteinase-activated receptors82Galanin receptorsQRFP receptorGhrelin receptor120Relaxin family peptide receptors121,122Glycoprotein hormone receptorsSomatostatin receptors123Gonadotropin-releasing hormone receptorsSuccinate receptor2Histamine receptors124,125Tachykinin receptorsHydroxycarboxylic acid receptors126Thyrotropin-releasing hormone receptorsKisspeptin receptor127Trace amine receptor128Leukotriene, lipoxin and 5-oxoeicosatrienoic acid receptors129, 130, 131Urotensin receptor132Lysophospholipid (LPA) receptors8,9Vasopressin and oxytocin receptorsLysophospholipid (S1P) receptors8,9The citations indicated are IUPHAR nomenclature publications in Pharmacological Reviews. Table 1Human class A G protein-coupled receptor families, which the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology considers have an established endogenous/physiological ligandFamilyFamily5-Hydroxytryptamine receptors88,89Melanin-concentrating hormone receptorsAcetylcholine receptors (muscarinic)90Melanocortin receptorsAdenosine receptors91,92Melatonin receptors93Adrenoceptors94,95Motilin receptorAngiotensin receptors96,97Neuromedin U receptorsApelin receptor98,99Neuropeptide FF/neuropeptide AF receptorsBile acid receptorNeuropeptide S receptorBombesin receptors100Neuropeptide W/neuropeptide B receptorsBradykinin receptors101Neuropeptide Y receptors102Cannabinoid receptors83,103Neurotensin receptorsChemerin receptors104Opioid receptorsChemokine receptors3,105, 106, 107Orexin receptors108,109Cholecystokinin receptors110Oxoglutarate receptor2Complement peptide receptors111P2Y receptors112Dopamine receptorsPlatelet-activating factor receptorEndothelin receptors113,114Prokineticin receptorsFormylpeptide receptors85Prolactin-releasing peptide receptorFree fatty acid receptors115Prostanoid receptors116, 117, 118G protein-coupled estrogen receptor119Proteinase-activated receptors82Galanin receptorsQRFP receptorGhrelin receptor120Relaxin family peptide receptors121,122Glycoprotein hormone receptorsSomatostatin receptors123Gonadotropin-releasing hormone receptorsSuccinate receptor2Histamine receptors124,125Tachykinin receptorsHydroxycarboxylic acid receptors126Thyrotropin-releasing hormone receptorsKisspeptin receptor127Trace amine receptor128Leukotriene, lipoxin and 5-oxoeicosatrienoic acid receptors129, 130, 131Urotensin receptor132Lysophospholipid (LPA) receptors8,9Vasopressin and oxytocin receptorsLysophospholipid (S1P) receptors8,9The citations indicated are IUPHAR nomenclature publications in Pharmacological Reviews. Human class A G protein-coupled receptor families, which the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology considers have an established endogenous/physiological ligand The citations indicated are IUPHAR nomenclature publications in Pharmacological Reviews. A further 17 class A orphan GPCRs are associated with NC-IUPHAR subcommittees and may be regarded as ”foster children” (Table 2). During the course of these discussions, the chemokine receptor subcommittee of NC-IUPHAR has suggested renaming GPR182 as the newest member of the atypical chemokine receptor subfamily, ACKR5.3 We highlight this group of GPCR “foster children” to identify that, in the near future, NC-IUPHAR subcommittee panels will apply the systematic criteria we identify here to assess the status of these GPCRs in more detail.Table 2Seventeen human class A orphan GPCR associated with the indicated NC-IUPHAR subcommittees (“foster children”)NC-IUPHAR subcommittee/sTarget/sAngiotensin receptorsMas1Bombesin receptorsBB3receptorP2Y receptorsLeukotriene receptorsGPR17Cannabinoid receptorsGPR18GPR55GPR119Chemokine receptorsGPR182Free fatty acid receptorsGPR42GPR84Leucine-rich repeat–containing receptorsLGR4LGR5LGR6Trace amine receptorsTAAR2TAAR5TAAR6TAAR8TAAR9NC-IUPHAR, Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology. Table 2Seventeen human class A orphan GPCR associated with the indicated NC-IUPHAR subcommittees (“foster children”)NC-IUPHAR subcommittee/sTarget/sAngiotensin receptorsMas1Bombesin receptorsBB3receptorP2Y receptorsLeukotriene receptorsGPR17Cannabinoid receptorsGPR18GPR55GPR119Chemokine receptorsGPR182Free fatty acid receptorsGPR42GPR84Leucine-rich repeat–containing receptorsLGR4LGR5LGR6Trace amine receptorsTAAR2TAAR5TAAR6TAAR8TAAR9NC-IUPHAR, Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology. Seventeen human class A orphan GPCR associated with the indicated NC-IUPHAR subcommittees (“foster children”) NC-IUPHAR, Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology. Here, we evaluate the remaining group of 67 Class A GPCRs for their orphan status in a systematic, pragmatic manner. Class A G protein-coupled receptor lacking a proposed endogenous/physiological ligand Although there are data regarding the molecular nature and tissue expression levels of 26 class A GPCRs (Table 3), currently, there are no published data suggesting endogenous/physiological ligands that may activate them. Synthetic ligands have been reported for 5 orphan GPCRs (GPR21, GPR27, GPR52, GPR85, and GPR88), although these still require independent validation (Table 3). By contrast, 6 of these orphan GPCRs (GPR135, GPR152, GPR153, MRGPRF, MRGPRG, and MRGPRX3) have no reported pharmacology and no phenotype for genetic disruption in the public domain. GPR135, GPR152, MRGPRE, and MRGPRG were expressed and screened against over 5000 endogenous compounds without identifying any hits.4 The Human Protein Atlas has combined bulk RNA sequencing data from 3 databases, but mRNA encoding GPR152 and MRGPRG was not detected in 50 human tissues or organs. However, low levels of GPR152 mRNA were reported following single-cell sequencing in endothelial cells and mononuclear phagocytes for the human heart. MRGPRG expression was also reported in specialized epithelial and germ cells using this technique. Only mRNA encoding GPR135 and GPR153 was reported to be widely distributed, although at low levels, with some evidence of protein expression using immunocytochemistry. GPR135 mRNA was reported to be present in human cancers using polymerase chain reaction.5 MRGPRE is reported in the brain and female reproductive organs, whereas MRGPRX3 is reported in the salivary glands. Other members of the Mas-related GPCR family were originally identified in sensory neurons, but more information is needed regarding the precise cellular expression of mRNA and protein that may indicate potential roles in humans.Table 3Twenty-five human class A orphan GPCR for which there are currently no identified endogenous/physiological ligandsTargetReported SignalingSurrogate LigandsPhenotype of Gene DisruptionaCommentsGPR20Reported to couple constitutively to Gi80,133--A cryo-EM structure of the recombinant GPR20 was suggested to compare with galanin receptors; the authors interpreted their observations to suggest the N terminus was able to activate the receptor in the absence of other ligands134GPR21Reported to couple constitutively to Gq135GRA2 is reported to act as an inverse agonist136Positive benefit in models of diabetes/obesity137,138 were not observed in another study139A complex mix of plasmalogens evoked phosphorylation of ERK and protein kinase B in mouse cultured hippocampal neurones that could be inhibited with shRNA directed against GPR21140A cryo-EM structure of unliganded GPR21 bound to G proteins has been reported141GPR22Reported to couple constitutively to Gi142,143-An increased susceptibility to cardiac decompensation following aortic banding142-GPR26Reported to couple constitutively to Gs144-Increased symptoms of anxiety and depression145, hyperphagia and adiposity146-GPR27Reported to couple constitutively to Gi805128535147, 148, 149 and PT-91149 functioned as surrogate agonists, whereas Compound 1a was reported as an inverse agonist,150 although a further study was unable to confirm this activity148A modestly reduced insulin gene transcription without altering glucose tolerance151Zebrafish showed altered insulin signaling and metabolite levels152A complex mix of plasmalogens evoked phosphorylation of ERK and protein kinase B in mouse cultured hippocampal neurones that could be inhibited with shRNA directed against GPR27140GPR33Heterologous expression of the mouse receptor resulted in elevated inositol phosphates levels153--GPR33 has been reported to bind radiolabeled cortisol.154Human GPR33 contains a premature stop codon within the coding sequence of the second intracellular loop153Pseudogenes of GPR33 predominantly occur in rodents (rat) and primates but not other mammals.153 Receptor inactivation may have occurred due to a rodent–hominoid-specific pathogen155Proposed to act as a viral anchoring site156GPR45Reported to couple constitutively to Gi80 and to Gs157-Increased adiposity at weaning and reduced hypothalamic expression of POMC.158Global disruption of Gpr45159 or selectively in the paraventricular nucleus of the hypothalamus was associated with obesity157-GPR52Reported to recruit β-arrestin constitutively in an inactive state160A number of synthetic agonists have been described, including compound 7a and 7m,161 FTBMT,162 derivative 17,163 BD442618, BD502657,164 HTL0041178,165 and sucralose166Additionally, multiple antagonists/inverse agonists have been reported, including cannabidiol, O1918,167 and comp-43168Elevated locomotor response to the A2A adenosine receptor antagonist istradefylline169A crystal structure of GPR52 with derivative 17 bound has been reported, with an interpretation that the ligand might act allosterically170GPR62Reported to couple constitutively to Gs171-No overt phenotype171 or impact on CNS myelination172Reported to inhibit MT2 receptor coupling to β-arrestin173GPR78Reported to couple constitutively to cAMP production144-Overexpression of GPR78 in mice was associated with a salivary gland dysfunction174Pubmed gets GPR78 confused with a 78 kDa glucose-regulated protein known as the endoplasmic reticulum chaperone BiPGPR82Reported to lack constitutive activity in recombinant expression80-A reduced body fat and weight, with increased insulin sensitivity and glucose tolerance175Although lacking constitutive activity in recombinant expression,80 LysoPE and LysoPC were reported to act as inverse agonists176GPR85Reported to lack constitutive activity in recombinant expression80Compound 1a150 and compound 3i177 are reported as inverse agonistsHarmine has been reported to act as an inverse agonist178Mild overexpression was associated with reduced brain mass, whereas increased brain mass was found in knockout animals179-GPR88Reported to couple to Gi143,180,181A number of small molecule agonists have been reported including 2-PCCA,b,182 RTI-122,183 RTI-13951-33,184,185 compound 2 [PMID: 24793972],181 compound 99,186 and BI-9508187Gene disruption resulted in altered striatal signaling,188 reduced adiposity and reduced spontaneous food intake,189 increased alcohol intake190A cryo-EM structure of GPR88 combined with Gi1 has been described, where 2-PCCA bound as an allosteric modulator191Reported to inhibit signaling through μ and δ opioid receptors192,193GPR135Reported to recruit β-arrestin constitutively, but failed to influence Gi/Gs pathways173--Reported to inhibit MT2 receptor coupling to β-arrestin173GPR141--Elevated immune response in leukocytes and experimental autoimmune encephalomyelitis194-GPR148---No orthologue exists in rodentsGPR149--Increased fertility in male mice,195 reduced oligodendrocyte progenitor cell maturation,196 and reduced weight gain on high-fat diet197-GPR150Reported to couple constitutively to Gi80---GPR152----GPR153Inferred to couple to Gi in a manner insensitive to pertussis toxin198-Reduced inflammatory signaling in models of stroke and experimental autoimmune encephalitis198-GPR161Appears to function as a negative regulator of Sonic hedgehog signaling199, 200, 201, 202-Reduced embryonic ciliary function203Variants of GPR161 are associated with developmental disorders in man204,205A cryo-EM structure suggests the second extracellular loop may auto-activate the receptor.81Reported to act as a mechanosensor in neuronal cilia206GPR176Reported to couple constitutively to Gi,80 to Gz in the suprachiasmatic nucleus207 and to Gs in colorectal cancer cells208-Knockout mice appeared superficially normal, but exhibited a shorter circadian period207Shows circadian variation in the suprachiasmatic nucleus.207 Activation of GPR176 was observed after co-incubation with a microwaved supernatant fraction from mouse brain209MRGPRF---Ang-1-7 was reported to inhibit arachidonic acid release in the presence of MRGPRF,210 although there was a lack of clarity whether this was an agonist or inverse agonist functionMRGPRG----MRGPRX3---Mrgprx3 is a pseudogene in miceCNS, central nervous system.aUnless noted otherwise, the phenotype is derived from mouse models.b(1R, 2R)-2-pyridin-2-yl-cyclopropane carboxylic acid ((2S, 3S)-2-amino-3-methyl-pentyl)-(4'-propylbiphenyl-4-yl)-amide. Table 3Twenty-five human class A orphan GPCR for which there are currently no identified endogenous/physiological ligandsTargetReported SignalingSurrogate LigandsPhenotype of Gene DisruptionaCommentsGPR20Reported to couple constitutively to Gi80,133--A cryo-EM structure of the recombinant GPR20 was suggested to compare with galanin receptors; the authors interpreted their observations to suggest the N terminus was able to activate the receptor in the absence of other ligands134GPR21Reported to couple constitutively to Gq135GRA2 is reported to act as an inverse agonist136Positive benefit in models of diabetes/obesity137,138 were not observed in another study139A complex mix of plasmalogens evoked phosphorylation of ERK and protein kinase B in mouse cultured hippocampal neurones that could be inhibited with shRNA directed against GPR21140A cryo-EM structure of unliganded GPR21 bound to G proteins has been reported141GPR22Reported to couple constitutively to Gi142,143-An increased susceptibility to cardiac decompensation following aortic banding142-GPR26Reported to couple constitutively to Gs144-Increased symptoms of anxiety and depression145, hyperphagia and adiposity146-GPR27Reported to couple constitutively to Gi805128535147, 148, 149 and PT-91149 functioned as surrogate agonists, whereas Compound 1a was reported as an inverse agonist,150 although a further study was unable to confirm this activity148A modestly reduced insulin gene transcription without altering glucose tolerance151Zebrafish showed altered insulin signaling and metabolite levels152A complex mix of plasmalogens evoked phosphorylation of ERK and protein kinase B in mouse cultured hippocampal neurones that could be inhibited with shRNA directed against GPR27140GPR33Heterologous expression of the mouse receptor resulted in elevated inositol phosphates levels153--GPR33 has been reported to bind radiolabeled cortisol.154Human GPR33 contains a premature stop codon within the coding sequence of the second intracellular loop153Pseudogenes of GPR33 predominantly occur in rodents (rat) and primates but not other mammals.153 Receptor inactivation may have occurred due to a rodent–hominoid-specific pathogen155Proposed to act as a viral anchoring site156GPR45Reported to couple constitutively to Gi80 and to Gs157-Increased adiposity at weaning and reduced hypothalamic expression of POMC.158Global disruption of Gpr45159 or selectively in the paraventricular nucleus of the hypothalamus was associated with obesity157-GPR52Reported to recruit β-arrestin constitutively in an inactive state160A number of synthetic agonists have been described, including compound 7a and 7m,161 FTBMT,162 derivative 17,163 BD442618, BD502657,164 HTL0041178,165 and sucralose166Additionally, multiple antagonists/inverse agonists have been reported, including cannabidiol, O1918,167 and comp-43168Elevated locomotor response to the A2A adenosine receptor antagonist istradefylline169A crystal structure of GPR52 with derivative 17 bound has been reported, with an interpretation that the ligand might act allosterically170GPR62Reported to couple constitutively to Gs171-No overt phenotype171 or impact on CNS myelination172Reported to inhibit MT2 receptor coupling to β-arrestin173GPR78Reported to couple constitutively to cAMP production144-Overexpression of GPR78 in mice was associated with a salivary gland dysfunction174Pubmed gets GPR78 confused with a 78 kDa glucose-regulated protein known as the endoplasmic reticulum chaperone BiPGPR82Reported to lack constitutive activity in recombinant expression80-A reduced body fat and weight, with increased insulin sensitivity and glucose tolerance175Although lacking constitutive activity in recombinant expression,80 LysoPE and LysoPC were reported to act as inverse agonists176GPR85Reported to lack constitutive activity in recombinant expression80Compound 1a150 and compound 3i177 are reported as inverse agonistsHarmine has been reported to act as an inverse agonist178Mild overexpression was associated with reduced brain mass, whereas increased brain mass was found in knockout animals179-GPR88Reported to couple to Gi143,180,181A number of small molecule agonists have been reported including 2-PCCA,b,182 RTI-122,183 RTI-13951-33,184,185 compound 2 [PMID: 24793972],181 compound 99,186 and BI-9508187Gene disruption resulted in altered striatal signaling,188 reduced adiposity and reduced spontaneous food intake,189 increased alcohol intake190A cryo-EM structure of GPR88 combined with Gi1 has been described, where 2-PCCA bound as an allosteric modulator191Reported to inhibit signaling through μ and δ opioid receptors192,193GPR135Reported to recruit β-arrestin constitutively, but failed to influence Gi/Gs pathways173--Reported to inhibit MT2 receptor coupling to β-arrestin173GPR141--Elevated immune response in leukocytes and experimental autoimmune encephalomyelitis194-GPR148---No orthologue exists in rodentsGPR149--Increased fertility in male mice,195 reduced oligodendrocyte progenitor cell maturation,196 and reduced weight gain on high-fat diet197-GPR150Reported to couple constitutively to Gi80---GPR152----GPR153Inferred to couple to Gi in a manner insensitive to pertussis toxin198-Reduced inflammatory signaling in models of stroke and experimental autoimmune encephalitis198-GPR161Appears to function as a negative regulator of Sonic hedgehog signaling199, 200, 201, 202-Reduced embryonic ciliary function203Variants of GPR161 are associated with developmental disorders in man204,205A cryo-EM structure suggests the second extracellular loop may auto-activate the receptor.81Reported to act as a mechanosensor in neuronal cilia206GPR176Reported to couple constitutively to Gi,80 to Gz in the suprachiasmatic nucleus207 and to Gs in colorectal cancer cells208-Knockout mice appeared superficially normal, but exhibited a shorter circadian period207Shows circadian variation in the suprachiasmatic nucleus.207 Activation of GPR176 was observed after co-incubation with a microwaved supernatant fraction from mouse brain209MRGPRF---Ang-1-7 was reported to inhibit arachidonic acid release in the presence of MRGPRF,210 although there was a lack of clarity whether this was an agonist or inverse agonist functionMRGPRG----MRGPRX3---Mrgprx3 is a pseudogene in miceCNS, central nervous system.aUnless noted otherwise, the phenotype is derived from mouse models.b(1R, 2R)-2-pyridin-2-yl-cyclopropane carboxylic acid ((2S, 3S)-2-amino-3-methyl-pentyl)-(4'-propylbiphenyl-4-yl)-amide. Twenty-five human class A orphan GPCR for which there are currently no identified endogenous/physiological ligands CNS, central nervous system. Unless noted otherwise, the phenotype is derived from mouse models. (1R, 2R)-2-pyridin-2-yl-cyclopropane carboxylic acid ((2S, 3S)-2-amino-3-methyl-pentyl)-(4'-propylbiphenyl-4-yl)-amide. One of the aspirations of this review is to highlight opportunities for further research. Given the wealth of drugs in clinical use that target GPCRs, in particular, from class A,6 we suggest that additional investigation of these 26 receptors could potentially lead to useful therapeutic opportunities. Developing criteria for the deorphanization process The remaining 41 GPCRs were considered to have sufficient published data to be subject to closer scrutiny. The expert reviewers (taken from the listed co-authors) were recruited based on their experience with the topic, while also reflecting diversity in geography and gender, as well as representing both academic and industrial roles. Each reviewer was allocated three GPCRs as a primary reviewer and 6 GPCRs as a second reviewer, with an aim to get an independent (unbiased) evaluation and triangulation of the status of those GPCRs. Reviewers were not allocated orphan GPCRs where they had published original articles on that receptor. The aim for the primary reviewers was to research the 3 assigned GPCRs and to update and/or correct the records in www.guidetopharmacology.org. In addition, primary reviewers summarized the evidence according to the evaluation checklist shown in Table 4. Secondary reviewers were not expected to research their topics to the same depth as primary reviewers but to accumulate sufficient evidence to make a judgment as to a 3-option outcome (strong, intermediate, and weak deorphanization cases evaluated as α, β, or γ—Table 5). For each receptor, at least 3 reviews were received. GPCRs were then ranked, both in terms of the judged strength of evidence and the convergence of evaluation from the reviewers. Thereafter, online sessions were conducted with the reviewers divided into 2 geographical sections, which allowed free discussions on the grading of the candidate GPCR across the entire panel of experts.Table 4Evaluation checklist used by reviewers of orphan G protein-coupled receptor1The cruxWhat is/are the suggested putative endogenous agonist/s?2ReproducibilityaHas the activity of this putative agonist been reproduced in the same signaling paradigm by a fully independent laboratory?abHas the receptor been included in a published major screening program and with what outcome?b3PhysiologycIs the potency of the putative agonist consistent with a physiological function?dAre there plausible mechanisms for the putative agonist to reach bioactive concentrations in tissues expressing the receptor?Is the ligand:receptor pairing physiologically feasible?4BindingHas binding of the putative agonist to the receptor been demonstrated?c5Agonist effectseWhat responses does the putative agonist evoke in cells expressing the recombinant receptor?dfWhat responses does the putative agonist evoke in native cells/tissues expressing the receptor?gDoes the putative agonist evoke a response in the absence of the receptor (off-target effects)?6PharmacologyhIf synthetic agonists have been described, how closely do they mimic the effects of the putative agonist?eiAre there antagonists that block the effects of the putative agonist (and/or synthetic agonists)?jDoes inhibition (pharmacological or genetic) of the enzymes capable of producing or terminating the putative agonist alter the receptor’s downstream signaling?7Genetic approacheskDo genetic alterations (natural mutations/single nucleotide polymorphisms or man-made), which alter receptor sequence or expression levels, disrupt cellular/tissue/behavioral responses to the putative agonist?lIn the case of peptide ligands, do genetic alterations of the coding gene result in changes in receptor expression?LysoPE, lysophosphatidylethanolamine.aWere cells/cDNA independently derived?.bFor example, Southern et al.4cThis might be displacement of labeled ligands or biophysical evidence. Although this is desirable, it would not be considered obligatory as it is often very challenging.dCalcium elevations, β-arrestin recruitment, cAMP inhibition, receptor internalisation, etc.eConsider the possibility of biased agonism.Table 5Evaluation options identified by reviewers of orphan G protein-coupled receptorα.Enough evidence from independent laboratories to establish a strong case for deorphanizationβ.Remains an orphan receptor with some evidence for endogenous ligands and/or function, but requires independent confirmationγ.Remains an orphan receptor with limited evidence for function Table 4Evaluation checklist used by reviewers of orphan G protein-coupled receptor1The cruxWhat is/are the suggested putative endogenous agonist/s?2ReproducibilityaHas the activity of this putative agonist been reproduced in the same signaling paradigm by a fully independent laboratory?abHas the receptor been included in a published major screening program and with what outcome?b3PhysiologycIs the potency of the putative agonist consistent with a physiological function?dAre there plausible mechanisms for the putative agonist to reach bioactive concentrations in tissues expressing the receptor?Is the ligand:receptor pairing physiologically feasible?4BindingHas binding of the putative agonist to the receptor been demonstrated?c5Agonist effectseWhat responses does the putative agonist evoke in cells expressing the recombinant receptor?dfWhat responses does the putative agonist evoke in native cells/tissues expressing the receptor?gDoes the putative agonist evoke a response in the absence of the receptor (off-target effects)?6PharmacologyhIf synthetic agonists have been described, how closely do they mimic the effects of the putative agonist?eiAre there antagonists that block the effects of the putative agonist (and/or synthetic agonists)?jDoes inhibition (pharmacological or genetic) of the enzymes capable of producing or terminating the putative agonist alter the receptor’s downstream signaling?7Genetic approacheskDo genetic alterations (natural mutations/single nucleotide polymorphisms or man-made), which alter receptor sequence or expression levels, disrupt cellular/tissue/behavioral responses to the putative agonist?lIn the case of peptide ligands, do genetic alterations of the coding gene result in changes in receptor expression?LysoPE, lysophosphatidylethanolamine.aWere cells/cDNA independently derived?.bFor example, Southern et al.4cThis might be displacement of labeled ligands or biophysical evidence. Although this is desirable, it would not be considered obligatory as it is often very challenging.dCalcium elevations, β-arrestin recruitment, cAMP inhibition, receptor internalisation, etc.eConsider the possibility of biased agonism. Evaluation checklist used by reviewers of orphan G protein-coupled receptor aHas the activity of this putative agonist been reproduced in the same signaling paradigm by a fully independent laboratory?a Has the activity of this putative agonist been reproduced in the same signaling paradigm by a fully independent laboratory?a bHas the receptor been included in a published major screening program and with what outcome?b Has the receptor been included in a published major screening program and with what outcome?b cIs the potency of the putative agonist consistent with a physiological function? Is the potency of the putative agonist consistent with a physiological function? dAre there plausible mechanisms for the putative agonist to reach bioactive concentrations in tissues expressing the receptor? Are there plausible mechanisms for the putative agonist to reach bioactive concentrations in tissues expressing the receptor? eWhat responses does the putative agonist evoke in cells expressing the recombinant receptor?d What responses does the putative agonist evoke in cells expressing the recombinant receptor?d fWhat responses does the putative agonist evoke in native cells/tissues expressing the receptor? What responses does the putative agonist evoke in native cells/tissues expressing the receptor? gDoes the putative agonist evoke a response in the absence of the receptor (off-target effects)? Does the putative agonist evoke a response in the absence of the receptor (off-target effects)? hIf synthetic agonists have been described, how closely do they mimic the effects of the putative agonist?e If synthetic agonists have been described, how closely do they mimic the effects of the putative agonist?e iAre there antagonists that block the effects of the putative agonist (and/or synthetic agonists)? Are there antagonists that block the effects of the putative agonist (and/or synthetic agonists)? jDoes inhibition (pharmacological or genetic) of the enzymes capable of producing or terminating the putative agonist alter the receptor’s downstream signaling? Does inhibition (pharmacological or genetic) of the enzymes capable of producing or terminating the putative agonist alter the receptor’s downstream signaling? kDo genetic alterations (natural mutations/single nucleotide polymorphisms or man-made), which alter receptor sequence or expression levels, disrupt cellular/tissue/behavioral responses to the putative agonist? Do genetic alterations (natural mutations/single nucleotide polymorphisms or man-made), which alter receptor sequence or expression levels, disrupt cellular/tissue/behavioral responses to the putative agonist? lIn the case of peptide ligands, do genetic alterations of the coding gene result in changes in receptor expression? In the case of peptide ligands, do genetic alterations of the coding gene result in changes in receptor expression? LysoPE, lysophosphatidylethanolamine. Were cells/cDNA independently derived?. For example, Southern et al.4 This might be displacement of labeled ligands or biophysical evidence. Although this is desirable, it would not be considered obligatory as it is often very challenging. Calcium elevations, β-arrestin recruitment, cAMP inhibition, receptor internalisation, etc. Consider the possibility of biased agonism. Table 5Evaluation options identified by reviewers of orphan G protein-coupled receptorα.Enough evidence from independent laboratories to establish a strong case for deorphanizationβ.Remains an orphan receptor with some evidence for endogenous ligands and/or function, but requires independent confirmationγ.Remains an orphan receptor with limited evidence for function Evaluation options identified by reviewers of orphan G protein-coupled receptor Of the criteria against which the receptors were compared, some are fundamental elements, such as the identification of a putative endogenous agonist (point 1) and the independent confirmation process (point 2). Point 2b identifies that literature searching for individual GPCRs may overlook mass screening investigations, such as Southern et al.4 Others relate to the physiological confirmation of the endogenous agonist (point 5) and whether tool compounds exist to dissect the pharmacological profile of the receptor (point 6). Genetic modification of the receptor, either as naturally occurring variants/single nucleotide polymorphisms or by molecular disruption (point 7), also provides evidence for the functional impact of the receptor. Of these criteria, it is worthwhile to reflect on 2 specific points. First, identifying binding of the putative endogenous ligand to the receptor (point 4) can be challenging for a number of reasons. The generation of a radiolabeled analog may be tricky in terms of synthetic chemistry. Fluorescent analogs may be equally challenging to synthesize. Additionally, many endogenous ligands bind at high nanomolar to low micromolar concentrations, which are difficult to quantify using conventional radioligand binding techniques. The likelihood of the ligand binding to other cellular components could also be a factor in limiting the levels of specific binding. We consider demonstration of binding of the putative endogenous agonist not to be an essential prerequisite, although it is a desirable confirmation. A more impactful criterion is whether there is the capacity to manipulate tissue levels of the putative endogenous ligand through modifying the enzyme activities involved in the synthesis or degradation/transformation of the ligand (point 6c). A requirement for this step is obviously that these enzyme activities are known and that inhibitors are available. Although this criterion is also a high bar to overcome, it allows distinction between ligands that can activate the receptor in vitro and those that really activate the receptor in situ. Orphan class A G protein-coupled receptors with a proposed endogenous/physiological ligand On the basis of triangulated reviews from the expert panel using these criteria, 31 GPCRs were identified as having limited evidence for deorphanization (Table 6). The most common reasons for this conclusion included a lack of confirmation by independent laboratories and questions about the physiological levels of the putative endogenous ligand/s in close proximity to the receptor, but particularly the “high bar” of the impact of manipulating levels of the putative endogenous agonist on receptor responsivity (point 6c).Table 6Thirty-two human class A orphan G protein-coupled receptor with reported putative endogenous/physiological agonists identified as having weak potential (rated β or γ by the reviewers) for deorphanization at the current timeTargetProposed Physiological Agonist/sSurrogate Agonist/sAntagonists/Inverse AgonistsCommentGPR3S1P211Oleic acid,212 ODA, and OEA212,213Diphenyleneiodonium212,214,215 and analogs216AF64394212,217 and cannabidiol218 are reported to act as inverse agonistsActivation by S1P was not repeated in β-arrestin assays4,20Fluorescent analogs of AF64394 have been reported to bind to the recombinant receptor219AF64394 is reported to bind to the membrane interface of a GPR3 homodimer based on cryo-EM studies220GPR6S1P211,221Palmitoleic acid212-Cannabidiol,218 CVN264222, 223, 224, 225, CVN-424 (Solengeprase)226 and CVN527227 are reported to act as inverse agonistsActivation by S1P was not repeated in β-arrestin assays4,20Reported to form functional heterodimers with LPA and S1P receptors228GPR12S1P211,221SPC229Oleic acid212Tyrosol230Multiple fungal-derived steroid-like compounds231Cannabidiol232 is reported to act as an inverse agonistActivation by S1P was not repeated in β-arrestin assays4,20GPR19Adropin233,234--Adropin was not effective in β-arrestin assays4,20Knockdown of Gpr19 in H9c2 rat cardiac cells235 or RAW264.7 mouse monocyte/macrophage cells236 resulted in a reduced responsiveness to adropin.Similarly, siRNA targeting of GPR19 in human primary fibroblasts attenuated the effects of adropin237GPR25CXCL17238,239--Reported to couple constitutively to Gi.80Nonmammalian orthologues are reported to be activated by apelin and apela240GPR32RvD1241,242Lipoxin A4242Resolvin D3243Compound 43242Multiple chemotypes were identified in a high-throughput screening assay241An antibody directed against GPR32 blocked RvD1-evoked responses in isolated human polymorphonuclear leukocytes244 and blocked RvD3-evoked responses in a recombinant GPR32-expressing cell line243Studies in macrophages that express GPR32 but not FPR2/ALX suggest RvD1 induced a pro-resolution phenotype (increased phagocytosis, blocked chemotaxis, reduced secretion of proinflammatory cytokines IL-1β, IL-8, and MCP-1). This effect was reduced with siRNA against GPR32 and was consistent with RvD1 as a pro-resolution molecule.245RvD1 was not effective in β-arrestin assays,4,20 or in dynamic mass redistribution or internalization assays.39Gpr32 is a pseudogene in mice and rats246Radioligand binding studies have been performed in a cell line that expresses the FPR1/ALX receptor, which is also a receptor for RvD1, and binding of RvD1 to GPR32 was inferred due to a binding remaining in the presence of FPR2/ALX agonist242GPR34LysoPS247, 248, 249, 250Compound 14 was reported as a high-potency synthetic agonist with selectivity relative to P2RY10251Compound M1 exhibited high potency in an assay for TGF-α shedding250M1 effects in primary microglia were lost following Gpr34 knockdown252YL-365253An antagonist has been claimed to block the effects of LysoPS in cultured cells, but a structure or source was not reported254 (S)-3-(4-(benzyloxy)phenyl)-2-(2-phenoxyacetamido) propanoic acid derivatives255Aminoethyl-carbamoyl ATP was identified as an antagonist at the carp orthologue248Compound D2256The stimulatory effects of LysoPS were not reproduced in alternative studies4,20,257Genetic disruption of iPLA2-G6 reduced LysoPS and mimicked the effects of Gpr34 knockdown in male mouse hearts258Cryo-EM structures of LysoPS bound to GPR34 have been described250,253,259GPR35Kynurenic acid4,260, 261, 2622-oleoyl-LysoPA2635,6-dihydroxyindole-2-carboxylic acid264CXCL172655HIAA266Z261,262,267, 268, 269NPPB261,270 pamoic acid261,262,269cromoglicic acid264,268,269nedocromil264,268entacapone262tyrphostin-51262furosemide271bumetanide271benserazide272pyrogallol272compound 83273lodoxamide274Isobavachin275Pelargonidin276CID2745687261,273ML145272,277There are large interspecies pharmacology differences between rat, mouse, and human GPR35. Kynurenic acid and zaprinast are up to 100-fold less potent at human than rat Gpr35, whereas pamoate is more active at the human receptor269The antagonists described are also higher affinity at the human orthologue compared to rodent receptorsHumans have 2 isoforms of GPR35, whereas rodents have only one278Isoforms show slightly different transducer coupling profiles/bias279The effects of the chemokine CXCL17 have been contradicted by 2 other studies274,280GPR37Prosaptide281 neuroprotectin D282Neuropeptide head activator283Prosaptide TX14282,284 chlorogenic acid285-Prosaptide and TX14 have both been reported as agonists of GPR37L1Although it was reported that mammalian tissues contain a peptide of identical amino acid sequence to Hydra head activator,286 there is currently no evidence for the presence of a gene encoding this peptide in any sequenced genome. However, the C-terminal tripeptide sequences of head activator and prosaptide are similar, which may explain the activity of head activator on GPR37Neuroprotectin D has been reported as an agonist at BLT1 receptors287Binding of TX14 and neuroprotectin D, but not RvE1, was reported to recombinant GPR37282GPR37L1Prosaptide281,284,288 maresin 1289--Maresin 1 is also reported to activate LGR6290GPR50Little-LEN bound to recombinant GPR50 in a cross-linking assay and inhibited cAMP formation291--Mice with disrupted GPR50 showed reduced body weight and lower gains on high-fat diet, increased levels of exercise,292 as well as an impaired social recognition293Reported to selectivity inhibit MT1 receptor, not MT2 receptor, function upon coexpression79Mitophagy may involve recruitment to the mitochondria293A ligand-free cryo-EM structure of GPR50 has been described294GPR61A complex mix of plasmalogens evoked phosphorylation of ERK and protein kinase B in mouse cultured hippocampal neurones that could be inhibited with shRNA directed against GPR611401-(1Z-octadecenyl)-2-oleoyl-sn-glycero-3-phosphoethanolamine295-Compound 1 was reported to act as an inverse agonist296Compound 15 was visualized bound to an intracellular site and acted as an inverse agonist297-GPR63S1P298,299 dioleoylphosphatidic acid298-Fingolimod appeared to function as an antagonist299S1P activation was not replicated.20Unlike the Xenopus orthologue, mammalian GPR63 was not responsive to LysoPA300GPR75CCL5/RANTES301,30220-HETE303,304(2-[[(5Z,14Z)-20-hydroxyicosa-5,14-dienoyl]amino]acetic acid305CCL5/RANTES30419-HEDE306Limonoid walrobsin A307N-disodium succinate-20-hydroxyeicosa-6 (Z), 15 (Z)- diencarboxamide (AAA)308Surface plasmon resonance provided evidence for 20-HETE binding to GPR7530420-HETE or CCL5 failed to evoke signaling with recombinant GPR75 in one report309A ligand-free cryo-EM structure of GPR75 has been described310GPR83Zn2+311PEN39,312, 313, 314FAM237A315, 316, 317FAM237B317CPD1, CPD27318CPD25318One study observed responses to FAM237A in the absence of responses to PEN with recombinant GPR83316A further report failed to provide evidence for PEN-evoked responses in GPR83-expressing cells or to exhibit specific binding of iodinated PENGPR87LysoPA319, 320, 321-Ki16425 and dioctanoylglycerol pyrophosphate319In comparison with LysoPA-evoked signaling via LPA1 receptors, LysoPA-evoked signaling through GPR87 was much reduced, and specific binding of 3H-LPA was not apparent322GPR101GnRH-1-5323,324N-3 Docosapentaenoic acid–derived resolvin D5325AA-14326--GPR139L-Phe and L-Trp327, 328, 329ACTH, α-MSH, and β-MSH39,328LP-360924330 compound 1a331 (S)-3-chloro-N-(2-oxo-2-((1-phenylethyl)amino)ethyl)benzamide Compound 7c332JNJ63533054327TC0931333JNJ63533054334AC4335 zelatriazin (TAK-041)336JNJ63533054337Compound 6338LP-471756330NCRW0105-E06338,339JNJ3792165333,338NCRW0005-F05338Activation by ACTH, α-MSH, and β-MSH was not replicated in a later study333Recombinant GPR139 has been labeled with 3H-JNJ63533054327,333A cryo-EM structure of an agonist-bound GPR139 has been described337GPR142L-Phe340L-Trp341Compound 33342Compound 22343Compound 22344Compound 33345Compound 40346Compound 20e347LY3325656348GPR146Proinsulin C-peptide349Cholesin C7orf50350A study using GPR146 revealed no response to C-peptide at concentrations of up to 33 μM351GPR151Galanin352Reported to be activated at acidic pH353--A later study was unable to observe responses to galanin39GPR160CARTp354--The suggestion that CARTp activates or binds to GPR160 has not been supported in two subsequent studies355,356GPR162CART(55–102)357---GPR171BigLEN358MS0015203359MS0021570_1360-GPR173GnRH-1-5361,362Phoenixin-14363, 364, 365Phoenixin-20364,366CCK-4 and CCK-8367-Compound 1a is reported as an inverse agonist150 devazepide and loxiglumide367GPR174LysoPS368, 369, 370CCL21371Compound 12370Compound 7d372Cryo-EM structures of LysoPS bound to GPR174 have been reported259,373,374MAS1LAngiotensin II, angiotensin IV, and Ang-(1–7)210---MRGPREA conjugate of tryptophan linked to cholic acid generated by the gut microbiome375---MRGPRX2Cortistatin4,376,377PAMP-20377, 378, 379, 380LL-37381β-Defensins382ATRA383CXCL14379CXCL17384Competence-stimulating peptide 1380PMX-53385 complanadine A386ZINC-3573387 compound 48/80380,388,389Murepavadin390Compound 1 and compound 2391GE1111392,393PSB172656379,394MRGPRX2 appears to respond to a wide range of basic compoundsMRGPRX4Deoxycholic acid and chenodeoxycholic acid395,396Lithocholic acid397Bilirubin398PSB22034, PSB22040399HEP50768400A cryo-EM structure of 3-sulfodeoxycholic acid bound to MRGPRX4 has been reported401Deoxycholic acid was ineffective in a β-arrestin screen of MRGPRX44MRGPRX4 orthologs are not found in rodentsP2RY8S-Geranylgeranyl-l-glutathione402--P2RY8 orthologs are not found in rodentsP2RY10LysoPA and S1P403LysoPS39,368, 369, 3709-o-C11370Compounds 22, 33, and 34404Compound 3r405Dioctanoylglycerol pyrophosphate403JTE-013403A later study was unable to observe responses to LysoPA395HIAA, 5-hydroxyindoleacetic acid; 19-HEDE, 19-hydroxyeicosa-5(Z) 14(Z)-dienoic acid; 20-HETE, 20-hydroxyeicosatetraenoic acid; ACTH, adrenocorticotropic hormone; ATRA, All-trans-retinoic acid; OEA, N-oleoylethanolamine; ODA, oleamide; LysoPA, lysophosphatidic acid; LysoPS, lysophosphatidylserine; ML145, CID2286812, 2-hydroxy-4-[4-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino]benzoic acid; MSH, melanocyte-stimulating hormone; RvD1, resolvin D1; SPC, sphingosylphosphorylcholine. Table 6Thirty-two human class A orphan G protein-coupled receptor with reported putative endogenous/physiological agonists identified as having weak potential (rated β or γ by the reviewers) for deorphanization at the current timeTargetProposed Physiological Agonist/sSurrogate Agonist/sAntagonists/Inverse AgonistsCommentGPR3S1P211Oleic acid,212 ODA, and OEA212,213Diphenyleneiodonium212,214,215 and analogs216AF64394212,217 and cannabidiol218 are reported to act as inverse agonistsActivation by S1P was not repeated in β-arrestin assays4,20Fluorescent analogs of AF64394 have been reported to bind to the recombinant receptor219AF64394 is reported to bind to the membrane interface of a GPR3 homodimer based on cryo-EM studies220GPR6S1P211,221Palmitoleic acid212-Cannabidiol,218 CVN264222, 223, 224, 225, CVN-424 (Solengeprase)226 and CVN527227 are reported to act as inverse agonistsActivation by S1P was not repeated in β-arrestin assays4,20Reported to form functional heterodimers with LPA and S1P receptors228GPR12S1P211,221SPC229Oleic acid212Tyrosol230Multiple fungal-derived steroid-like compounds231Cannabidiol232 is reported to act as an inverse agonistActivation by S1P was not repeated in β-arrestin assays4,20GPR19Adropin233,234--Adropin was not effective in β-arrestin assays4,20Knockdown of Gpr19 in H9c2 rat cardiac cells235 or RAW264.7 mouse monocyte/macrophage cells236 resulted in a reduced responsiveness to adropin.Similarly, siRNA targeting of GPR19 in human primary fibroblasts attenuated the effects of adropin237GPR25CXCL17238,239--Reported to couple constitutively to Gi.80Nonmammalian orthologues are reported to be activated by apelin and apela240GPR32RvD1241,242Lipoxin A4242Resolvin D3243Compound 43242Multiple chemotypes were identified in a high-throughput screening assay241An antibody directed against GPR32 blocked RvD1-evoked responses in isolated human polymorphonuclear leukocytes244 and blocked RvD3-evoked responses in a recombinant GPR32-expressing cell line243Studies in macrophages that express GPR32 but not FPR2/ALX suggest RvD1 induced a pro-resolution phenotype (increased phagocytosis, blocked chemotaxis, reduced secretion of proinflammatory cytokines IL-1β, IL-8, and MCP-1). This effect was reduced with siRNA against GPR32 and was consistent with RvD1 as a pro-resolution molecule.245RvD1 was not effective in β-arrestin assays,4,20 or in dynamic mass redistribution or internalization assays.39Gpr32 is a pseudogene in mice and rats246Radioligand binding studies have been performed in a cell line that expresses the FPR1/ALX receptor, which is also a receptor for RvD1, and binding of RvD1 to GPR32 was inferred due to a binding remaining in the presence of FPR2/ALX agonist242GPR34LysoPS247, 248, 249, 250Compound 14 was reported as a high-potency synthetic agonist with selectivity relative to P2RY10251Compound M1 exhibited high potency in an assay for TGF-α shedding250M1 effects in primary microglia were lost following Gpr34 knockdown252YL-365253An antagonist has been claimed to block the effects of LysoPS in cultured cells, but a structure or source was not reported254 (S)-3-(4-(benzyloxy)phenyl)-2-(2-phenoxyacetamido) propanoic acid derivatives255Aminoethyl-carbamoyl ATP was identified as an antagonist at the carp orthologue248Compound D2256The stimulatory effects of LysoPS were not reproduced in alternative studies4,20,257Genetic disruption of iPLA2-G6 reduced LysoPS and mimicked the effects of Gpr34 knockdown in male mouse hearts258Cryo-EM structures of LysoPS bound to GPR34 have been described250,253,259GPR35Kynurenic acid4,260, 261, 2622-oleoyl-LysoPA2635,6-dihydroxyindole-2-carboxylic acid264CXCL172655HIAA266Z261,262,267, 268, 269NPPB261,270 pamoic acid261,262,269cromoglicic acid264,268,269nedocromil264,268entacapone262tyrphostin-51262furosemide271bumetanide271benserazide272pyrogallol272compound 83273lodoxamide274Isobavachin275Pelargonidin276CID2745687261,273ML145272,277There are large interspecies pharmacology differences between rat, mouse, and human GPR35. Kynurenic acid and zaprinast are up to 100-fold less potent at human than rat Gpr35, whereas pamoate is more active at the human receptor269The antagonists described are also higher affinity at the human orthologue compared to rodent receptorsHumans have 2 isoforms of GPR35, whereas rodents have only one278Isoforms show slightly different transducer coupling profiles/bias279The effects of the chemokine CXCL17 have been contradicted by 2 other studies274,280GPR37Prosaptide281 neuroprotectin D282Neuropeptide head activator283Prosaptide TX14282,284 chlorogenic acid285-Prosaptide and TX14 have both been reported as agonists of GPR37L1Although it was reported that mammalian tissues contain a peptide of identical amino acid sequence to Hydra head activator,286 there is currently no evidence for the presence of a gene encoding this peptide in any sequenced genome. However, the C-terminal tripeptide sequences of head activator and prosaptide are similar, which may explain the activity of head activator on GPR37Neuroprotectin D has been reported as an agonist at BLT1 receptors287Binding of TX14 and neuroprotectin D, but not RvE1, was reported to recombinant GPR37282GPR37L1Prosaptide281,284,288 maresin 1289--Maresin 1 is also reported to activate LGR6290GPR50Little-LEN bound to recombinant GPR50 in a cross-linking assay and inhibited cAMP formation291--Mice with disrupted GPR50 showed reduced body weight and lower gains on high-fat diet, increased levels of exercise,292 as well as an impaired social recognition293Reported to selectivity inhibit MT1 receptor, not MT2 receptor, function upon coexpression79Mitophagy may involve recruitment to the mitochondria293A ligand-free cryo-EM structure of GPR50 has been described294GPR61A complex mix of plasmalogens evoked phosphorylation of ERK and protein kinase B in mouse cultured hippocampal neurones that could be inhibited with shRNA directed against GPR611401-(1Z-octadecenyl)-2-oleoyl-sn-glycero-3-phosphoethanolamine295-Compound 1 was reported to act as an inverse agonist296Compound 15 was visualized bound to an intracellular site and acted as an inverse agonist297-GPR63S1P298,299 dioleoylphosphatidic acid298-Fingolimod appeared to function as an antagonist299S1P activation was not replicated.20Unlike the Xenopus orthologue, mammalian GPR63 was not responsive to LysoPA300GPR75CCL5/RANTES301,30220-HETE303,304(2-[[(5Z,14Z)-20-hydroxyicosa-5,14-dienoyl]amino]acetic acid305CCL5/RANTES30419-HEDE306Limonoid walrobsin A307N-disodium succinate-20-hydroxyeicosa-6 (Z), 15 (Z)- diencarboxamide (AAA)308Surface plasmon resonance provided evidence for 20-HETE binding to GPR7530420-HETE or CCL5 failed to evoke signaling with recombinant GPR75 in one report309A ligand-free cryo-EM structure of GPR75 has been described310GPR83Zn2+311PEN39,312, 313, 314FAM237A315, 316, 317FAM237B317CPD1, CPD27318CPD25318One study observed responses to FAM237A in the absence of responses to PEN with recombinant GPR83316A further report failed to provide evidence for PEN-evoked responses in GPR83-expressing cells or to exhibit specific binding of iodinated PENGPR87LysoPA319, 320, 321-Ki16425 and dioctanoylglycerol pyrophosphate319In comparison with LysoPA-evoked signaling via LPA1 receptors, LysoPA-evoked signaling through GPR87 was much reduced, and specific binding of 3H-LPA was not apparent322GPR101GnRH-1-5323,324N-3 Docosapentaenoic acid–derived resolvin D5325AA-14326--GPR139L-Phe and L-Trp327, 328, 329ACTH, α-MSH, and β-MSH39,328LP-360924330 compound 1a331 (S)-3-chloro-N-(2-oxo-2-((1-phenylethyl)amino)ethyl)benzamide Compound 7c332JNJ63533054327TC0931333JNJ63533054334AC4335 zelatriazin (TAK-041)336JNJ63533054337Compound 6338LP-471756330NCRW0105-E06338,339JNJ3792165333,338NCRW0005-F05338Activation by ACTH, α-MSH, and β-MSH was not replicated in a later study333Recombinant GPR139 has been labeled with 3H-JNJ63533054327,333A cryo-EM structure of an agonist-bound GPR139 has been described337GPR142L-Phe340L-Trp341Compound 33342Compound 22343Compound 22344Compound 33345Compound 40346Compound 20e347LY3325656348GPR146Proinsulin C-peptide349Cholesin C7orf50350A study using GPR146 revealed no response to C-peptide at concentrations of up to 33 μM351GPR151Galanin352Reported to be activated at acidic pH353--A later study was unable to observe responses to galanin39GPR160CARTp354--The suggestion that CARTp activates or binds to GPR160 has not been supported in two subsequent studies355,356GPR162CART(55–102)357---GPR171BigLEN358MS0015203359MS0021570_1360-GPR173GnRH-1-5361,362Phoenixin-14363, 364, 365Phoenixin-20364,366CCK-4 and CCK-8367-Compound 1a is reported as an inverse agonist150 devazepide and loxiglumide367GPR174LysoPS368, 369, 370CCL21371Compound 12370Compound 7d372Cryo-EM structures of LysoPS bound to GPR174 have been reported259,373,374MAS1LAngiotensin II, angiotensin IV, and Ang-(1–7)210---MRGPREA conjugate of tryptophan linked to cholic acid generated by the gut microbiome375---MRGPRX2Cortistatin4,376,377PAMP-20377, 378, 379, 380LL-37381β-Defensins382ATRA383CXCL14379CXCL17384Competence-stimulating peptide 1380PMX-53385 complanadine A386ZINC-3573387 compound 48/80380,388,389Murepavadin390Compound 1 and compound 2391GE1111392,393PSB172656379,394MRGPRX2 appears to respond to a wide range of basic compoundsMRGPRX4Deoxycholic acid and chenodeoxycholic acid395,396Lithocholic acid397Bilirubin398PSB22034, PSB22040399HEP50768400A cryo-EM structure of 3-sulfodeoxycholic acid bound to MRGPRX4 has been reported401Deoxycholic acid was ineffective in a β-arrestin screen of MRGPRX44MRGPRX4 orthologs are not found in rodentsP2RY8S-Geranylgeranyl-l-glutathione402--P2RY8 orthologs are not found in rodentsP2RY10LysoPA and S1P403LysoPS39,368, 369, 3709-o-C11370Compounds 22, 33, and 34404Compound 3r405Dioctanoylglycerol pyrophosphate403JTE-013403A later study was unable to observe responses to LysoPA395HIAA, 5-hydroxyindoleacetic acid; 19-HEDE, 19-hydroxyeicosa-5(Z) 14(Z)-dienoic acid; 20-HETE, 20-hydroxyeicosatetraenoic acid; ACTH, adrenocorticotropic hormone; ATRA, All-trans-retinoic acid; OEA, N-oleoylethanolamine; ODA, oleamide; LysoPA, lysophosphatidic acid; LysoPS, lysophosphatidylserine; ML145, CID2286812, 2-hydroxy-4-[4-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino]benzoic acid; MSH, melanocyte-stimulating hormone; RvD1, resolvin D1; SPC, sphingosylphosphorylcholine. Thirty-two human class A orphan G protein-coupled receptor with reported putative endogenous/physiological agonists identified as having weak potential (rated β or γ by the reviewers) for deorphanization at the current time 5HIAA, 5-hydroxyindoleacetic acid; 19-HEDE, 19-hydroxyeicosa-5(Z) 14(Z)-dienoic acid; 20-HETE, 20-hydroxyeicosatetraenoic acid; ACTH, adrenocorticotropic hormone; ATRA, All-trans-retinoic acid; OEA, N-oleoylethanolamine; ODA, oleamide; LysoPA, lysophosphatidic acid; LysoPS, lysophosphatidylserine; ML145, CID2286812, 2-hydroxy-4-[4-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino]benzoic acid; MSH, melanocyte-stimulating hormone; RvD1, resolvin D1; SPC, sphingosylphosphorylcholine. Analysis of the putative ligands for this group of orphan GPCRs suggests 3 major chemical classes: lipids and their derivatives, peptides, and other metabolites. Multiple orphan GPCRs have been suggested to respond to lipids, including the lysophospholipids sphingosine 1-phosphate (S1P) (GPR3, GPR6, GPR12, GPR63, and P2RY10) and lysophosphatidic acid (GPR35, GPR87, and P2RY10) (Table 6). These 2 endogenous lysophospholipids activate 2 families of receptors that have some overlapping sequence similarities, such that S1P1, S1P2, S1P3, S1P4, S1P5, and LPA1, LPA2, and LPA3 receptors were initially described as a protein family derived from 8 endothelial differentiation genes.7, 8, 9 However, later-identified members of the LPA receptor family, LPA4 and LPA6, were sufficiently different in sequence that they were initially proposed as members of the P2Y receptor family.10,11 This illustrates the observation that although sequence similarities are useful as preliminary guides for nomenclature, the overriding factor in determining nomenclature must be pharmacological evidence.12 Other lipid derivatives suggested to activate orphan GPCRs in this group include fatty acids (GPR3, GPR6, and GPR12), lysophosphatidylserine (GPR34, GPR174, and P2RY10), phospholipids and their derivatives (GPR61 and GPR63), and a variety of oxidized fatty acid metabolites, including 20-hydroxyeicosatetraenoic acid (GPR75), lipoxin A4 (GPR32), maresin 1 (GPR37L1), neuroprotectin D1 (GPR37), and resolvin analogs (GPR32 and GPR101). Ring-based lipids, including isoprenoid derivatives (MRGPRX2 and all-trans-retinoic acid; P2RY8 and S-geranylgeranyl-l-glutathione) and steroid derivatives (MRGPRE and a cholic acid conjugate; MRGPRX4 and cholic acid derivatives), are also reported to activate orphan GPCRs in this group. Two GPCRs (GPR139 and GPR142) have been proposed to respond to aromatic amino acids, whereas several other orphan GPCRs have been suggested to be activated by oligopeptides active at established GPCRs, ranging from CCK-4 (GPR173) and the pentapeptide metabolite of gonadotropin-releasing hormone (GPR101 and GPR173), to various metabolites of angiotensin II (MAS1L) and galanin (GPR151). Three orphan GPCRs (GPR25, GPR35, and MRGPRX2) have been reported to respond to the endogenous chemokine-like mediator CXCL17, whereas other chemokines have been reported to activate GPR75 and GPR174 (Table 6). Other, less well-characterized peptides have been reported to activate GPR19, GPR37, GPR37L1, GPR83, GPR146, GPR160, GPR162, GPR171, GPR173, and MRGPRX2 (see Table 6). The remaining candidate endogenous ligands could be loosely grouped as metabolites, ranging from the inorganic agents, protons (GPR151) and zinc ions (GPR83) to amino acid and monoamine metabolites (GPR35) and bilirubin (MRGPRX4). Based on these data, it would be a recommendation from NC-IUPHAR for further independent investigation of these preliminary pairings; of particular focus would be an assessment of the colocalization of patho/physiologically relevant concentrations of the putative endogenous agonist with the target GPCR. Orphan class A G protein-coupled receptors with substantive evidence supporting endogenous/physiological ligand identification For this group of class A GPCRs, the expert reviewers completed initial, independent assessments, which led to discussions across the whole group to reach a consensus, which evaluated them as stronger candidates for deorphanization (Table 7). As with the previous group lacking convincing evidence for deorphanization (Table 6), the putative endogenous ligands could initially be subdivided based on chemical classes.Table 7Ten human class A orphan G protein-coupled receptor evaluated for orphan status and identified as having high potential for deorphanization at the current timeTargetProposed Endogenous/Physiological Agonist/sSurrogate Agonist/sAntagonists/Inverse AgonistsCommentGPR4Protons48,49,406, 407, 408-Compound 1409GPR4 antagonist 3b410Compound 39c411NE 52-QQ57412, 413, 414Cryo-EM structures have been reported54,415, 416, 417, 418GPR15GPR15L37,38,40,419GPR15L (71-81)39,419-Antibodies directed against GPR15 were described to block GPR15L-mediated T-cell recruitment420Binding of modified GPR15L to GPR15 has been reported38,40,419,421A cryo-EM structure of GPR15 with GPR15L bound has been described422GPR15L has also been reported to activate CXCR4 in vitro423GPR3112S-HETE13,14,424,425SB583831 and SB58335521SAH2424Radiolabeled 12S-HETE binding to recombinant GPR31 has been described13,42512S-HETE was ineffective in a β-arrestin screen of GPR314GPR39Zn2+66,67,70,426TC-G 1008427 compound 15428Cpmd1324429,430VC43431Compound 61432Knockdown of GPR39 in human HaCaT keratinocytes attenuated zinc-evoked responses69A PET ligand for GPR39 in vivo has been described433GPR65Protons48,50,408,434-Psychosine appeared to act as an agonist at the recombinant receptor,435 although a later report suggested antagonist action at acid-induced signaling50BTB09089 was initially reported as a positive allosteric modulator of GPR65,436,437 and then later suggested to target RhoA instead438GPR68Protons48,49,408,436,439,440-Ogremorphin441Compound 18l442MS48107,443 ogerin,436 and lorazepam55,436 have been described as positive allosteric modulatorsA cryo-EM structure has been described418GPR1329-HODE19,21,25,444ONC212445CP55940, SKF95667, SB583831, and SB58335521NOX-6-725T10418444GSK1820795A21NOX-6-18259-HODE, N-palmitoylglycine, and N-linoleoylglycine were ineffective in a β-arrestin screen of GPR1324Crystal structures of GPR132 have been described with bound N-palmitoylglycine or 9 (S)-hydroxy-10,12-octadecadienoic acid25GPR1837α,25-dihydroxycholesterol31, 32, 33,446, 447, 448, 4497α,27-OHC, 7α-OHC, 7β-OHC, 7β, 27-OHC, 7β, 25-OHC, 25-OHC, OHC31,32,446NIBR51448T10418444GSK682753A450,451NIBR189448SAE14452 compound 32453compound 33447Radiolabeled 7α,25-diOHC binding to recombinant GPR183 has been described31,32,450Cryo-EM structures of GPR183 bound with GSK682753A and 7α,25-diOHC have been reported454MRGPRDβ-alanine4,56, 57, 58,455Alamandine60Diethylstilbestrol58EP2825 and EP3945455MU684058PD12331960D-Pro7-Ang-(1–7)62Alamandine and β-alanine displaced binding of a fluorescently labeled alamandine peptide in recombinant MRGPRD expression59Cryo-EM structures have been reported of MRGPRD bound with EP2825 and EP3945455MRGPRX1Bovine adrenal medulla peptide 8-224,42, 43, 44, 45Chloroquine456 compound 16457,458FSLLRY459 fungal micasin460Berbamine459,461ML382 is reported as a positive allosteric modulator of the receptor.43Cryo-EM structures of MRGPRX1 bound with BAM8-22 have been described,458,462 as well as the synthetic agonist compound 16463OHC, hydroxycholesterol. Table 7Ten human class A orphan G protein-coupled receptor evaluated for orphan status and identified as having high potential for deorphanization at the current timeTargetProposed Endogenous/Physiological Agonist/sSurrogate Agonist/sAntagonists/Inverse AgonistsCommentGPR4Protons48,49,406, 407, 408-Compound 1409GPR4 antagonist 3b410Compound 39c411NE 52-QQ57412, 413, 414Cryo-EM structures have been reported54,415, 416, 417, 418GPR15GPR15L37,38,40,419GPR15L (71-81)39,419-Antibodies directed against GPR15 were described to block GPR15L-mediated T-cell recruitment420Binding of modified GPR15L to GPR15 has been reported38,40,419,421A cryo-EM structure of GPR15 with GPR15L bound has been described422GPR15L has also been reported to activate CXCR4 in vitro423GPR3112S-HETE13,14,424,425SB583831 and SB58335521SAH2424Radiolabeled 12S-HETE binding to recombinant GPR31 has been described13,42512S-HETE was ineffective in a β-arrestin screen of GPR314GPR39Zn2+66,67,70,426TC-G 1008427 compound 15428Cpmd1324429,430VC43431Compound 61432Knockdown of GPR39 in human HaCaT keratinocytes attenuated zinc-evoked responses69A PET ligand for GPR39 in vivo has been described433GPR65Protons48,50,408,434-Psychosine appeared to act as an agonist at the recombinant receptor,435 although a later report suggested antagonist action at acid-induced signaling50BTB09089 was initially reported as a positive allosteric modulator of GPR65,436,437 and then later suggested to target RhoA instead438GPR68Protons48,49,408,436,439,440-Ogremorphin441Compound 18l442MS48107,443 ogerin,436 and lorazepam55,436 have been described as positive allosteric modulatorsA cryo-EM structure has been described418GPR1329-HODE19,21,25,444ONC212445CP55940, SKF95667, SB583831, and SB58335521NOX-6-725T10418444GSK1820795A21NOX-6-18259-HODE, N-palmitoylglycine, and N-linoleoylglycine were ineffective in a β-arrestin screen of GPR1324Crystal structures of GPR132 have been described with bound N-palmitoylglycine or 9 (S)-hydroxy-10,12-octadecadienoic acid25GPR1837α,25-dihydroxycholesterol31, 32, 33,446, 447, 448, 4497α,27-OHC, 7α-OHC, 7β-OHC, 7β, 27-OHC, 7β, 25-OHC, 25-OHC, OHC31,32,446NIBR51448T10418444GSK682753A450,451NIBR189448SAE14452 compound 32453compound 33447Radiolabeled 7α,25-diOHC binding to recombinant GPR183 has been described31,32,450Cryo-EM structures of GPR183 bound with GSK682753A and 7α,25-diOHC have been reported454MRGPRDβ-alanine4,56, 57, 58,455Alamandine60Diethylstilbestrol58EP2825 and EP3945455MU684058PD12331960D-Pro7-Ang-(1–7)62Alamandine and β-alanine displaced binding of a fluorescently labeled alamandine peptide in recombinant MRGPRD expression59Cryo-EM structures have been reported of MRGPRD bound with EP2825 and EP3945455MRGPRX1Bovine adrenal medulla peptide 8-224,42, 43, 44, 45Chloroquine456 compound 16457,458FSLLRY459 fungal micasin460Berbamine459,461ML382 is reported as a positive allosteric modulator of the receptor.43Cryo-EM structures of MRGPRX1 bound with BAM8-22 have been described,458,462 as well as the synthetic agonist compound 16463OHC, hydroxycholesterol. Ten human class A orphan G protein-coupled receptor evaluated for orphan status and identified as having high potential for deorphanization at the current time OHC, hydroxycholesterol. Potential lipid-sensing G protein-coupled receptors: GPR31, GPR132, and GPR183 For all 3 of these GPCRs, synthetic agonists and antagonists have been described, which should facilitate the broader characterization of pathophysiological signaling. GPR31: 12S-Hydroxyeicosatetraenoic acid (12S-HETE, (5Z,8Z,10E,12S,14Z)-12-hydroxyeicosa-5,8,10,14-tetraenoic acid) is derived from arachidonic acid through 12S-lipoxygenase activity. 12S-HETE was initially described to activate GPR31 in recombinant systems in 2011.13 The authors investigated the potential for binding of a radiolabeled version, which they observed to have high affinity (pKd value of 8.3). Functional analysis of these cells identified 12S-HETE-enhanced binding of guanosine 5′-O-(3-[35S]thio)triphosphate with a potency of 9.5 (pEC50 value) and activation of extracellular signal-regulated kinase. In an independent analysis, 300 nM 12S-HETE inhibited cAMP-mediated reporter gene expression in CHO cells expressing human recombinant GPR31.14 In a model of liver ischemia-reperfusion injury, symptoms were abated in an identical manner by interfering with either 12S-lipoxygenase or GPR31.15 It should be noted that lactate and pyruvate have also been suggested to activate GPR31,16, 17, 18 and knockdown of GPR31 in human intestinal dendritic cells attenuated pyruvate-evoked responses.16 Although the evidence for activation by 12S-HETE appears consistent in mouse and human recombinant receptors, evidence for the protein expression of GPR31 in human tissues is limited. GPR132: Particular oxylipins, oxidized metabolites of fatty acids, increased guanosine 5′-O-(3-[35S]thio)triphosphate or binding, inositol phosphates accumulation, and elevated intracellular calcium in cells expressing recombinant GPR132.19 Specifically, 9(S)-hydroxyoctadecadienoic acid (9S-HODE), derived from linoleic acid, and 11-hydroxy-5,8,12,14-eicosatetraenoic acid, derived from arachidonic acid, are possible agonists. The potency of 9S-HODE for calcium mobilization was ∼5.6 (pEC50 value). 9S-HODE and 11-hydroxy-5,8,12,14-eicosatetraenoic acid were confirmed as agonists in independent studies using recombinant GPR132, measuring β-arrestin accumulation,20 and a yeast pheromone gene assay replicated the potency of 9S-HODE with a pEC50 value of 5.9.21 One reservation noted was that the reported plasma concentration of 9-hydroxyoctadecadienoic acid was 58 nM in healthy rats,22 although inflammation increased tissue levels in the sciatic nerve from ∼150 to over 400 pmol/mg tissue.23 GPR132 has also been reported to be activated by amino acid conjugates of fatty acids, including N-(3-hydroxypalmitoyl)glycine,24 N-palmitoylglycine,21,25 and N-linoleoylglycine,21 although cryo-EM studies suggested a different binding profile compared with oxidized fatty acids.25 There is contradictory literature about the impact of lysophospholipids on GPR132 function. Responses to lysophosphatidylcholine (LysoPC) in isolated human neutrophils were blocked by an antibody directed at GPR132,26 whereas a report that LysoPC and sphingosylphosphorylcholine activated GPR132 has been retracted,27 as has a report suggesting activation of GPR132 by LysoPC.28 Multiple reports suggest that LysoPC26,28 and LysoPS26 can activate GPR132 in vitro. LysoPC was also reported to block the effects of protons on GPR132 signaling.29 Whether these actions of lipid metabolites are mediated through an orthosteric or allosteric mechanism (see discussion below for GPR68) awaits further investigation. GPR183: Oxysterols are a family of sterol derivatives, among which 7α,25-dihydroxycholesterol (7α,25-diOHC) is formed by the sequential hydroxylation of cholesterol by cholesterol 25-hydroxylase and CYP7B1.30 Subsequent turnover of 7α,25-diOHC is mediated by hydroxyl-Δ-5-steroid dehydrogenase, 3β- and steroid Δ-isomerase 7, leading to the production of bile acids.30 Two publications in 2011 identified that 7α,25-diOHC activated recombinant GPR18331,32 with potencies (pEC50 values) of 8.9 (guanosine 5′-O-(3-[35S]thio)triphosphate binding) and 8.7 (calcium mobilization). 3H-7α,25-diOHC was observed to bind specifically to the recombinant receptor by different groups with a range of Kd values of 450 pM32 to 24 nM.33 Modification of the expression of cholesterol 25-hydroxylase, a synthetic enzyme for oxysterols, altered signaling through GPR183.31,34, 35, 36 Potential peptide-sensing G protein-coupled receptors: GPR15 and MRGPRX1 For these GPCRs, there are limited examples of synthetic agonists and antagonists, which will hamper further characterization of these receptors. GPR15: A highly cationic 81-aa polypeptide with chemokine-like properties, isolated from pig gut, activated recombinant GPR15 in calcium mobilization assays.37 A truncated peptide identified as GPR15L-(25-81) exhibited a potency (pEC50 value) of ∼7.5 in this assay. An independent investigation, building on a patent disclosure, described the potency of full-length “GPR15L” in a GPR15-β-arrestin assay of 7.7.38 Other fragments of or modified peptides from “GPR15L” were reported to activate recombinant GPR15 in assays of cAMP inhibition with a potency of 6.739 or ERK activation with a potency of ∼8.2.40 A fusion protein of “GPR15L” with the fragment crystallizable portion of human IgG bound specifically to cells expressing recombinant GPR15, but not to untransfected cells. The potency (pIC50 value) for “GPR15L” displacement of fusion protein binding was ∼7.0.38 Fragments of cystatin C have been proposed to activate GPR15, although through a distinct mechanism of action.41 Previous guidance on receptor nomenclature from NC-IUPHAR recommended that a receptor be named after its endogenous agonist.1,12 The potential re-naming of GPR15 is complicated, however, by the sequence of discovery, where an endogenous peptide was identified after the receptor was identified and named after the GPCR. MRGPRX1: Proenkephalin A is a protein precursor of the endogenous opioid pentapeptide enkephalins but also produces a 22-aa fragment called bovine adrenal medulla peptide 22, which was found to activate the δ-opioid peptide receptor in vitro, as well as MRGPRX1.42 A truncated version, bovine adrenal medulla peptide 8-22 (BAM-8-22), exhibited selective activation of MRGPRX1 for calcium mobilization, with a potency (pEC50 value) of 7.5, without activity at δ opioid peptide receptor up to micromolar concentrations.42 Activation of MRGPRX1 by BAM-8-22 has been reproduced in subsequent independent investigations.4,43, 44, 45 Specific binding of 3H-BAM-8-22 was observed using recombinant MRGPRX1 with a pKd value of ∼8.0.42 Chemokine CXCL17 has been reported to activate MRGPRX1 in vitro.46 Peptide fragments of hemoglobin (hemorphins LVV-H7 and VV-H7) were identified in human platelets and activated recombinant MRGPRX1, albeit with much lower potency than BAM-8-22.47 Studies in rodents are confounded because they lack orthologues of this receptor, so it will be challenging to investigate the manipulation of proenkephalin A expression and its influence on MRGPRX1 activity. A potential family of proton-sensing G protein-coupled receptors: GPR4, GPR65, and GPR68 In normal plasma and extracellular fluids, pH is tightly regulated, but in inflammatory states and with some cancers, extracellular pH can drop below 7.3, which may have implications for signal transduction. At the time of writing, these 3 GPCRs have a limited repertoire of synthetic pharmacological tools, so an aspiration of this review is that more widespread attention on these receptors should facilitate drug discovery in this area. GPR4, GPR65, and GPR68 constitute a subfamily with higher homology to each other in comparison to the remaining class A GPCRs. One common feature is a series of 3–5 extracellular histidine residues combined with a triad of “buried” acidic glutamate and aspartate residues.48 It is suggested that superficial histidines act as proton sensors, leading to intramolecular rearrangements allowing the deeper acidic residues to promote coupling to G proteins, although the 3 orphans appear to have slightly different thresholds for proton activation. As indicated in Table 7, multiple independent reports support the influence of pathophysiological changes in extracellular pH as the stimulus for coupling of these 3 receptors to elevation of intracellular cAMP in the case of GPR449 and GPR6550 or to calcium and cAMP signaling by GPR68.49,51 Membrane lysophospholipids have been suggested to influence the function of this family of GPCR, although there is a lack of clarity in terms of whether these effects are consistent and/or a mechanism of allosteric regulation. For example, a report of GPR4 activation by sphingosylphosphorylcholine and LysoPC has been retracted27 as has a report that sphingosylphosphorylcholine activated GPR68.52 Lysophosphatidic acid activation of the LPA1 receptor has been reported to facilitate GPR68 action in vitro.53 A recent cryo-EM study suggested that LysoPC bound to GPR4 allosterically to enhance receptor function.54 GPR68 was also reported to respond to a number of endogenous peptides: OSTN (115-133), CARTPT (76-96), and Pomc (141-162).39 This report has not yet been reproduced. Sulazepam was described to act as a low-potency inverse agonist for GPR68.55 MRGPRD β-Alanine is a naturally occurring alternative amino acid in mammalian systems, resulting from pyrimidine degradation, which has also been of interest as a potential anabolic dietary supplement and precursor for the dipeptide carnosine. β-Alanine evoked calcium mobilization and inhibition of cAMP formation in MRGPRD-expressing cells with a potency (pEC50 value) of 4.8.56 Responses of MRGPRD to similar concentrations of β-alanine were confirmed by several subsequent independent investigations.4,57,58 Decarboxylation of the amino terminus of angiotensin-1-7 converts aspartate to alanine, producing a heptapeptide named alamandine. It is suggested to be formed in the heart from Ang-1-7 metabolism and to be present in the blood.59 In cells expressing MRGPRD, alamandine evoked cAMP formation with a bell-shaped profile, in which the stimulatory phase had a potency (pEC50 value) of 12.4.60 Although alamandine has biological effects in preparations in which MRGPRD is expressed and is sensitive to a reported MRGPRD antagonist61, 62, 63, 64, the pairing does not appear to have been reproduced with the recombinant receptor. There remains, therefore, a need for triangulation of observations, as well as the demonstration of pathophysiological levels of the putative endogenous agonists for MRGPRD. GPR39 Zinc is an essential trace element, with multiple transporters identified for translocation of zinc ions in mammalian cells, and an estimated 10% of the human proteome has been identified as zinc-binding proteins.65 Extracellular concentrations of zinc ions in the micromolar range were found to enhance inositol phosphates and cAMP generation in GPR39-expressing cells with potencies (pEC50 values) of 4.7 and 5.1, respectively.66 A contemporaneous report identified that fractions of FBS that activated GPR39-expressing cells could be eliminated in the presence of EDTA.67 In these cells, micromolar zinc ion concentrations evoked rapid intracellular calcium ion elevations. GPR39 activation by zinc ions has been proposed as a result of synaptic activity68 or damage.69 The suggested locus for zinc ion binding to GPR39 is through 2 N-terminal histidine residues.70 Although this location for a canonical orthosteric ligand would be unique for a class A GPCR, the possibility has been raised that it is consistent with an allosteric ligand. It has been reported that a fragment from the ghrelin precursor called obestatin was an agonist for GPR39.71 However, several independent groups have been unable to replicate this finding.66,72, 73, 74 The original authors have since confirmed that they could not reproduce their findings on obestatin binding and activation of GPR39 in vitro.75 Two alternative, potentially orthosteric oxylipin agonists have been proposed for GPR39: 15-HETE (15-hydroxyeicosatetraenoic acid) and 14,15-epoxyeicosatrienoic acid.76 In a search for binding proteins for 14,15-epoxyeicosatrienoic acid, an irreversible probe labeled GPR39 in mouse vascular smooth muscle cells. Among the other oxylipins investigated, only 15-HETE was also able to evoke extracellular signal-regulated kinase activation in transfected cells.76 The responses to these eicosanoids were enhanced in the presence of 1 μM zinc ions, a concentration that was ineffective alone. Zinc ions and 15-HETE were also synergistic when intracellular calcium ions were measured in mouse vascular smooth muscle cells. Notably, 15-HETE and 14,15-epoxyeicosatrienoic acid were ineffective in a β-arrestin screen of GPR39.4 To conclude, therefore, the relationship between GPR39, zinc ions, and eicosanoid/oxylipin analogs needs clarifying before a change in nomenclature is warranted. Conclusions In this review, we have provided an extended evaluation checklist for NC-IUPHAR subcommittees to conduct an unbiased evaluation of the orphan status of class A GPCRs, and indeed for all receptors. Information about 10 of the orphan class A GPCRs (Table 7) is sufficiently advanced that we can refer these to further subcommittees of NC-IUPHAR. We would advocate for the wider community to continue investigating these suggested pairings—independent confirmation is a fundamental in science. Cell-based assay kits are available commercially to assist in those investigations, which should facilitate the investigations of receptor pharmacology. However, there remain challenges associated with determining the levels of endogenous ligands in the close environment of the receptor. In addition, for some of the putative endogenous/physiological ligands described, the enzymatic pathways for production and transformation remain obscure. In considering the substantial numbers of class A GPCRs lacking a putative endogenous agonist or any substantive pharmacology (Table 3), we are prompted to pose a number of questions: Does every GPCR need to have an endogenous agonist or physiological ligand? As with the ACKR family of atypical chemokine receptors, the possibility exists for a singular modality (e.g., through β-arrestin)3 rather than multiple downstream signaling pathways, and so we may consider that, for some of these receptors, the “correct” combination of agonist and signaling pathway may not have been tested. A further possibility is that some receptors may only be functional as part of an oligomeric complex. For family C GPCRs, there are examples of obligate heterodimers such as the GABAB receptor77 and the sweet taste receptor, TAS1R2/TAS1R3.78 Although the same profile has not been described for class A GPCRs, a heterodimer between GPR50 and the MT1 receptor has been described, in which GPR50 exerted an inhibitory effect on MT1 receptor function.79 A number of class A orphan GPCRs have been described as having high constitutive activity in recombinant expression,80 whether this results from the particular cellular environment or from intrinsic structural properties of these receptors will require further investigation. GPR161 provides an example where there is evidence for autoactivation of the receptor by an intrinsic peptide sequence81 in a manner distinct from the proteinase-activated receptors.82 Does every GPCR need to respond to a single endogenous ligand (or ligand family)? For the cannabinoid receptors, there are 2 distinct families of endogenous ligands, based on esters, such as 2-arachidonoylglycerol, and amides, such as anandamide,83 whereas opioid receptors have multiple endogenous peptide agonists.84 The nomenclature for such examples will need to be resolved on a case-by-case basis. Additionally, there are examples of GPCRs for which the physiological agonist is derived from exogenous sources. For example, fMet-Leu-Phe is a bacterial product that activates formylpeptide receptors and prompts chemotaxis in neutrophils.85 Similar GPCRs in the mouth and nasal passages, the taste and odorant receptors, would be expected to respond to dietary and environmental stimuli, although they are also expressed in internal organs separated from the exterior.86 Does every species orthologue need to respond to the same endogenous ligand? Certainly, there are “complications” of evolution, which imply that orthologues may not be highly conserved across species, leading to distinct pharmacology. This is most obviously evident in the bitter taste receptors86 and the Mas-related GPCR family,87 where different receptor repertoires and distinct pharmacology are evident in human and rodent species. In summary, although advances are being made in our understanding of the pharmacology, physiology, and biochemistry of these incredibly useful drug targets, it is apparent that there are still major opportunities for the future exploitation of these class A GPCRs. Conflict of interest Authors Stephen P.H. Alexander, Kirstie A. Bennett, Elena Faccenda, Julien Hanson, Paul A. Insel, Simon D. Harding, Eamonn Kelly, Kirill A. Martemyanov, Rick R. Neubig, Stefan Offermanns, Gunnar Schulte, Nicola J. Smith declare no conflict of interest. Andrew J. Brown was an employee of GlaxoSmithKline at the time of writing the manuscript and provides consultancy services to Rewind Therapeutics, Schrodinger, Linchpin.Bio, and Mironid. Michelle Glass is a consultant for Aelis Farma Ltd. David E. Gloriam is a part-time employee and warrant holder of Kvantify. Christopher J. Langmead holds shares in GlaxoSmithKline Ltd, Pacalis Therapeutics Pty Ltd and Phrenix Therapeutics Inc. He is also a part-time employee of Phrenix Therapeutics Pty Ltd and is the recipient of research funding from Servier. Pacalis, Phrenix, and Servier are all engaged in GPCR drug discovery. Christopher J. Langmead has also received payment for consultancy from Neumora Therapeutics Inc and Curie.Bio. Mette M. Rosenkilde is co-founder and minor shareholder of Antag Therapeutics and Synklino, and consultant at Aikium. Huixian Wu is an employee of Pfizer Inc. Anthony P. Davenport is a member of scientific advisory boards on endothelin for Johnson & Johnson, ENB Therapeutics and Pharmazz.